Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPuente, Javier-
dc.contributor.authorLainez, Nuria-
dc.contributor.authorDueñas, Marta-
dc.contributor.authorMéndez-Vidal, María José-
dc.contributor.authorEsteban, Emilio-
dc.contributor.authorCastellano, Daniel-
dc.contributor.authorMartinez-Fernández, Mónica-
dc.contributor.authorBasterretxea, Laura-
dc.contributor.authorJuan Fita, María José-
dc.contributor.authorAntón, Luis-
dc.contributor.authorLeón, Luis-
dc.contributor.authorLambea, Julio-
dc.contributor.authorPérez-Valderrama, Begoña-
dc.contributor.authorVázquez, Sergio-
dc.contributor.authorSuarez, Cristina-
dc.contributor.authorGarcía del Muro Solans, Xavier-
dc.contributor.authorGallardo, Enrique-
dc.contributor.authorMaroto, José Pablo-
dc.contributor.authorSamaniego, M. Luz-
dc.contributor.authorSuárez-Paniagua, Beatriz-
dc.contributor.authorSanz, Julián-
dc.contributor.authorParamio, Jesús M.-
dc.contributor.authorSOGUG (Spanish Oncology Genitourinary Group)-
dc.description.abstractBackground: several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. Patients and methods: multicenter, observational, retrospective study in patients with clear-cell mRCC treated with sunitinib. Patients were classified in two groups: long-term responders (LR) (progression-free survival (PFS)≥22 months and at least stable disease), and primary refractory (PR) (progressive disease within 3-months of sunitinib onset). Objectives were to compare baseline clinical factors in both populations and to correlate tumor expression of selected signaling pathways components with sunitinib PFS. Results: 123 patients were analyzed (97 LR, 26 PR). In the LR cohort, overall response rate was 79% and median duration of best response was 30 months. Median PFS and overall survival were 43.2 (95% confidence intervals[CI]:37.2-49.3) and 63.5 months (95%CI:55.1-71.9), respectively. At baseline PR patients had a significantly lower proportion of nephrectomies, higher lactate dehydrogenase and platelets levels, lower hemoglobin, shorter time to and higher presence of metastases, and increased Fuhrman grade. Higher levels of HEYL, HEY and HES1 were observed in LR, although only HEYL discriminated populations significantly (AUC[ROC]=0.704; cut-off=34.85). Increased levels of hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p were also associated with prolonged survival. No statistical significant associations between hsa-miR-23b or hsa-miR-27b and the expression of c-Met were found. Conclusions: certain mRCC patients treated with sunitinib achieve extremely long-term responses. Favorable baseline hematology values and longer time to metastasis may predict longer PFS. HEYL, hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p could be potentially used as biomarkers of sunitinib response.-
dc.format.extent12 p.-
dc.publisherImpact Journals-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofOncotarget, 2017, vol. 8, num. 18, p. 30410-30421-
dc.rightscc-by (c) Puente, Javier et al., 2017-
dc.subject.classificationMarcadors bioquímics-
dc.subject.classificationCàncer de ronyó-
dc.subject.otherBiochemical markers-
dc.subject.otherRenal cancer-
dc.titleNovel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
680095.pdf5.47 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons